Organon & CO Form 4 insider transactions

Organon & Co.'s Head of Global Business Services, Vittorio Nisita, reported the acquisition of common stock through performance share unit vesting and dividend equivalents, alongside related tax withholdings.

Organon & Co.'s Chief Information Officer, Rachel A. Stahler, reported the vesting of performance share units and related share transactions, increasing her beneficial ownership.

Organon & Co.'s General Counsel, Kirke Weaver, increased beneficial ownership of common stock through the vesting of performance share units and dividend equivalents.

Organon & Co.'s Interim CEO, Joseph T. Morrissey Jr., reported the acquisition and disposition of common stock related to performance share unit vesting and dividend equivalents.

Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Drinane, amended a previous SEC filing to correct a reported share acquisition to a disposal for tax liability.

Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Drinane, was granted 65,616 Restricted Stock Units.

Organon & Co.'s Interim CEO, Joseph T. Morrissey Jr., was granted 131,233 Restricted Stock Units, vesting over three years.

Organon & Co.'s Executive Chair, Carrie Smith Cox, purchased 65,400 shares of common stock indirectly through an IRA at a weighted average price of $7.6721.

Juliana Drinane, Interim Head of Manufacturing & Supply at Organon & Co., increased her direct beneficial ownership of common stock following the vesting of restricted stock units.

Organon's Head of R&D and CMO, Juan Camilo Arjona Ferreira, reported the acquisition of common stock through RSU vesting and subsequent sale for tax withholding.

Organon & Co.'s SVP and Corporate Controller, Lynette Holzbaur, reported future transactions involving common stock and restricted stock units.

Organon & Co.'s SVP and Corporate Controller, Lynette Holzbaur, reported the acquisition of common stock from restricted stock unit vesting and a subsequent sale for tax withholding.

Organon & Co.'s Head of R&D and CMO, Juan Camilo Arjona Ferreira, increased his direct ownership of common stock following the vesting of restricted stock units and a tax-related sale.

Organon & Co. Director Ramona Sequeira was granted 21,890.547 phantom stock units, effective July 1, 2025, as part of the company's Non-Employee Director Savings Plan.

Organon & Co. Director Philip Ozuah reported the acquisition of 23,904.382 phantom stock units on June 13, 2025, increasing his total beneficial ownership to 62,702.657 units.

Organon & Co. Director Deborah R. Leone acquired 23,904.382 phantom stock units on June 13, 2025, increasing her total beneficial ownership to 62,702.655 units.

Organon & Co. Director Shalini Sharp has acquired 23,904.382 phantom stock units, increasing her total beneficial ownership to 63,054.148 units, as reported in a recent SEC Form 4 filing.

Organon & Co. Director Cynthia M. Patton acquired 23,904.382 phantom stock units on June 13, 2025, increasing her total beneficial ownership to 62,702.653 units.

Organon & Co. Director Grace Puma Whiteford has reported an increase in her beneficial ownership of phantom stock units, primarily through dividend reinvestment and a new grant, as disclosed in a recent SEC Form 4 filing.

Organon & Co. Director Rochelle B. Lazarus acquired 23,904.382 phantom stock units on June 13, 2025, as part of the company's Non-Employee Director Savings Plan.

Organon & Co. Director Helene D. Gayle has acquired 23,904.382 phantom stock units through the company's Non-Employee Director Savings Plan, increasing her total beneficial ownership to 62,702.656 units.

Organon & Co. Director Alan Ezekowitz has increased his beneficial ownership in the company by acquiring 23,904.382 phantom stock units, bringing his total holdings to 62,702.653 units.

Organon & Co. Director Robert Essner has increased his beneficial ownership in the company through the acquisition of phantom stock units, as disclosed in a recent SEC Form 4 filing.

Organon & Co. Director Carrie Smith Cox acquired 23,904.382 phantom stock units valued at $10.04 per unit, increasing her total beneficial ownership to 74,029.769 units.

Director Carrie Smith Cox purchased 12,469 shares of Organon & Co. common stock at a weighted average price of $8.0673 on May 14, 2025.

Aaron Falcione, Chief Human Resources Officer of Organon & Co., reports the acquisition of 5,500 shares of common stock at a price of $8.77 per share on May 7, 2025.

Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reports the acquisition of 8,045 shares of common stock at $9.205 per share on May 6, 2025.

Executive Vice President of Corporate Development at Organon & Co., Daniel Karp, purchased 3,500 shares of common stock at a price of $8.2366 per share on May 6, 2025.

Matthew M. Walsh, CFO of Organon & Co., reports acquiring 11,400 shares of common stock at $8.82 per share on May 5, 2025, increasing his total holdings to 144,484 shares.

Organon & Co.'s CEO, Kevin Ali, recently purchased 34,000 shares of the company's common stock at an average price of $8.805 per share.